Elanco Animal Health to Acquire Kindred Biosciences

Eli Lilly to Acquire Vaccine Company for Up to $1.55 Billion

May 27, 2026

Biotechnology

Vaccine Company, Inc. announced it has entered into a definitive agreement to be acquired by Eli Lilly and Company in a deal valued at up to $1.55 billion, including upfront and milestone-based payments. The acquisition is intended to accelerate development of Vaccine Company’s next-generation in vivo nanoparticle (IVN) vaccine platform, led by a Phase 1-ready Epstein-Barr virus (EBV) vaccine candidate targeting infectious mononucleosis and longer-term EBV-linked diseases.

Eli Lilly Acquires Kelonia Therapeutics for Up to $7 Billion

April 20, 2026

Biotechnology

Eli Lilly has announced a definitive agreement to acquire Kelonia Therapeutics, a clinical-stage biotechnology company developing in vivo CAR-T cell therapy via its proprietary gene delivery platform. The deal is valued at up to $7 billion, including a $3.25 billion upfront payment, with additional clinical, regulatory, and commercial milestone payments. Closing is expected in the second half of 2026, subject to customary approvals.

Merck Animal Health Acquires Elanco’s Aqua Business

February 6, 2024

Healthcare Services

Elanco Animal Health has agreed to sell its aqua business to Merck Animal Health for approximately $1.3 billion in cash. The divestiture includes aqua products and brands, aqua R&D projects, transfer of manufacturing sites in Prince Edward Island (Canada) and Dong Nai (Vietnam), and about 280 commercial and manufacturing employees, with closing expected around mid-year subject to regulatory approvals.

Merck to Acquire Acceleron Pharma Inc for $11.5B

September 30, 2021

Biotechnology

Merck (through a subsidiary) entered into a definitive agreement to acquire Acceleron Pharma Inc for $180 per share in cash, for an approximate total equity value of $11.5 billion. The transaction will be completed via a tender offer followed by a merger, and is expected to close in the fourth quarter of 2021, subject to conditions including regulatory approvals and tender of at least a majority of outstanding shares.

LifePoint Health Acquires Kindred Healthcare

June 21, 2021

Healthcare Services

LifePoint Health agreed to acquire Kindred Healthcare in June 2021 and completed the transaction in December 2021, combining LifePoint's community hospital network with Kindred's long-term acute care, rehabilitation and behavioral health capabilities. The deal created a new national system, ScionHealth, and LifePoint committed to invest roughly $1.5 billion over three years to expand services, technology and community-based care.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.